Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › warfarin

warfarin

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of warfarin

70 trials tracked of warfarin: 31 in phase 3 or 4 and 10 with published results. The most-cited published study has 440 citations.

70Trials tracked
31Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 12 Phase 3 19 Phase 2 12 Phase 1 10 Other / NA 17
  1. Phase 4 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed · 440 cited
  2. Phase 3 A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT) Completed · 311 cited
  3. Phase 3 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) Completed · 248 cited
  4. Phase 4 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed · 230 cited
  5. Phase 3 Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy Completed · 132 cited
  6. Phase 4 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed · 46 cited
Show 44 more trials
  1. Phase 3 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation Completed · 32 cited
  2. Phase 3 Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Completed · 22 cited
  3. Phase 4 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation Completed · 15 cited
  4. Phase 3 Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation Completed · 9 cited
  5. Phase 4 A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir) Completed
  6. Phase 4 Clinical and Economic Implications of Genetic Testing for Warfarin Management Completed
  7. Phase 4 Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy Completed
  8. Phase 4 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium Completed
  9. Phase 4 A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Completed
  10. Phase 4 Treatment of Upper Extremity Deep-Vein Thrombosis Completed
  11. Phase 4 Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy Completed
  12. Phase 4 Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers Completed
  13. Phase 3 AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients Completed
  14. Phase 3 Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus Completed
  15. Phase 3 WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation Completed
  16. Phase 3 Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer Completed
  17. Phase 3 Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial Completed
  18. Phase 3 Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Completed
  19. Phase 3 Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) Completed
  20. Phase 3 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
  21. Phase 3 Secondary Prevention of Venous Thrombo Embolism (VTE). Completed
  22. Phase 3 Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation Completed
  23. Phase 3 Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate Completed
  24. Phase 3 An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation Completed
  25. Phase 3 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed
  26. Phase 2 PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin Completed
  27. Phase 2 Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients Completed
  28. Phase 2 Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection Completed
  29. Phase 2 Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices Completed
  30. Phase 2 A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin Completed
  31. Phase 2 A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis Completed
  32. Phase 2 Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin Completed
  33. Phase 2 Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation Completed
  34. Phase 2 A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation Completed
  35. Phase 2 A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation Completed
  36. Phase 2 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma Completed
  37. Phase 2 Odiparcil For The Prevention Of Venous Thromboembolism Completed
  38. Phase 1 The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin Completed
  39. Phase 1 A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants Completed
  40. Phase 1 A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants Completed
  41. Phase 1 Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin Completed
  42. Phase 1 Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin Completed
  43. Phase 1 A Study of LY2216684 and Warfarin in Healthy Subjects Completed
  44. Phase 1 Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers Completed

Showing the 50 most-cited and recently-updated of 70 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE
Cardiology FDA Approval
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE FDA approves a new blood thinner called Xarelto for several heart and clot conditions
The FDA approved rivaroxaban (Xarelto), a factor Xa inhibitor, for multiple indications including reducing stroke risk in nonvalvular atrial…
FDA approves new blood thinner Xarelto to prevent dangerous clots in heart conditions, deep vein issues, and after major surgeries.
FDA Mar 31, 2026